Agora, Inc. Reports Third Quarter 2025 Financial Results

Agora, Inc. Reports Third Quarter 2025 Financial Results GlobeNewswire November 19, 2025 SANTA CLARA, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) — Agora, Inc. (NASDAQ: API) (the “Company”), a pioneer and leader in conversational AI and real-time engagement technology, today announced its unaudited financial results for the third quarter ended September 30, 2025. “We're pleased to […]

NOV Announces Retirement of Clay Williams and Appointment of Jose Bayardo as CEO, Effective January 1, 2026

NOV Announces Retirement of Clay Williams and Appointment of Jose Bayardo as CEO, Effective January 1, 2026 GlobeNewswire November 19, 2025 HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) — NOV Inc. announced today that Clay Williams, Chairman and Chief Executive Officer will retire, and Jose Bayardo, NOV's current President and Chief Operating Officer, will succeed him

AutoZone to Release First Quarter Fiscal 2026 Earnings December 9, 2025

AutoZone to Release First Quarter Fiscal 2026 Earnings December 9, 2025 GlobeNewswire November 19, 2025 MEMPHIS, Tenn., Nov. 19, 2025 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO), the leading retailer and distributor of automotive replacement parts and accessories in the Americas, will release results for its first quarter ended Saturday, November 22, 2025, before market

RGC Resources, Inc. Reports 2025 Earnings

(NasdaqGM:RGCO), ROANOKE, Va., Nov. 19, 2025 (GLOBE NEWSWIRE) — RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $13.3 million, or $1.29 per share, for the fiscal year ended September 30, 2025, compared to $11.8 million, or $1.16 per share, for the fiscal year ended September 30, 2024. The strong increase reflected record levels

RGC Resources, Inc. Reports 2025 Earnings

RGC Resources, Inc. Reports 2025 Earnings GlobeNewswire November 19, 2025 ROANOKE, Va., Nov. 19, 2025 (GLOBE NEWSWIRE) — RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $13.3 million, or $1.29 per share, for the fiscal year ended September 30, 2025, compared to $11.8 million, or $1.16 per share, for the fiscal year ended

Ardent Health (ARDT) Faces Investor Scrutiny Amid Problems Estimating Collection of Accounts Receivable, Disclosure Drives Stock Down 33% — Hagens Berman

On November 13, 2025 investors in healthcare services provider Ardent Health (NYSE: ARDT) saw the price of their shares tumble $4.75 (-33%) after the company announced its Q3 2025 financial results, widely missing consensus EPS estimates and revealing two adverse items characterized as non-recurring. https://mma.prnewswire.com/media/2590203/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg The developments and significant market reaction has prompted shareholder rights

Manasquan Bank Named a 2025 Best Banks to Work by American Banker

Manasquan Bank is pleased to announce it has been honored once again by American Banker a Best Bank to Work For. The Best Companies Group (BCG) compiles the annual list. https://mma.prnewswire.com/media/2211104/ManasquanBank_Logo.jpg Manasquan Bank ranked #27 among U.S. banks recognized as “Best Banks” in 2025, in all asset size categories and #1 in New Jersey. Additionally,

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Freeport-McMoRan Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FCX

(NYSE:FCX), NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Freeport-McMoRan Inc. (NYSE: FCX) between February 15, 2022 and September 24, 2025, both dates inclusive (the “Class Period”). A class action

MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman

(NASDAQ:MLTX), SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) — A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or “SLK”), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa

Xcel Brands, Inc. Announces Third Quarter 2025 Financial Results

(NASDAQ:XELB), Net loss on a GAAP basis was $7.9 million for the current quarter and $14.7 million on a year-to-date basis, inclusive of various non-cash charges. Net loss on a non-GAAP basis was $1.3 million for the current quarter and $3.6 million for the current year-to-date. Current quarter Adjusted EBITDA for 2025 was negative $0.65

Scroll to Top